Clidinium (Br)
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Clidinium (Br) is antimuscarinic drug. Clidinium (Br) is used in the treatment of peptic ulcers. It slows the activity of the stomach and intestinal tract and relieves cramping and reduces acid secretion.
Indications
Clidinium (Br) is primarily indicated in conditions like Spasticity, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer.
Contraindications
Clidinium (Br) is contraindicated in conditions like Hypersensitivity to any component of product.
Side Effects
The symptomatic adverse reactions produced by Clidinium (Br) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dry mouth, Mydriasis, Urinary hesitancy, Xerostomia, Cycloplegia, Skin eruptions, Nausea, Xerostomia.
Warnings
Risk of drowsiness. Performance of activities requiring mental alertness and physical coordination (e.g., operating a vehicle or other machinery, performing hazardous work) may be impaired. (See Advice to Patients.)
Exposure to high environmental temperatures may result in heat prostration in patients receiving antimuscarinics. Increased risk of hyperthermia in patients with fever. Use with caution in patients who may be exposed to elevated environmental temperatures or in febrile patients.
Diarrhea may be an early sign of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy; use with extreme caution.
Clidinium is commercially available in the US only in fixed combination with chlordiazepoxide hydrochloride. Consider cautions, precautions, and contraindications associated with chlordiazepoxide.
Caution in patients with ulcerative colitis; large doses may suppress intestinal motility, resulting in paralytic ileus and toxic megacolon.
Category C.
Not known whether clidinium is distributed into milk.
Risk of lactation suppression.
Safety and efficacy of clidinium bromide in fixed combination with chlordiazepoxide hydrochloride not established in pediatric patients.
Use with caution in geriatric patients. Geriatric patients may be prone to adverse effects (e.g., drowsiness, ataxia, confusion) when receiving clidinium bromide in fixed combination with chlordiazepoxide hydrochloride. Such adverse effects may occur even at the lower end of dosage range. (See Geriatric Patients under Dosage and Administration.)
Use with caution in patients with hepatic disease.
Use with caution in patients with renal disease.
High Risk Groups
Risk of drowsiness. Performance of activities requiring mental alertness and physical coordination (e.g., operating a vehicle or other machinery, performing hazardous work) may be impaired. (See Advice to Patients.)
Exposure to high environmental temperatures may result in heat prostration in patients receiving antimuscarinics. Increased risk of hyperthermia in patients with fever. Use with caution in patients who may be exposed to elevated environmental temperatures or in febrile patients.
Diarrhea may be an early sign of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy; use with extreme caution.
Clidinium is commercially available in the US only in fixed combination with chlordiazepoxide hydrochloride. Consider cautions, precautions, and contraindications associated with chlordiazepoxide.
Caution in patients with ulcerative colitis; large doses may suppress intestinal motility, resulting in paralytic ileus and toxic megacolon.
Category C.
Not known whether clidinium is distributed into milk.
Risk of lactation suppression.
Safety and efficacy of clidinium bromide in fixed combination with chlordiazepoxide hydrochloride not established in pediatric patients.
Use with caution in geriatric patients. Geriatric patients may be prone to adverse effects (e.g., drowsiness, ataxia, confusion) when receiving clidinium bromide in fixed combination with chlordiazepoxide hydrochloride. Such adverse effects may occur even at the lower end of dosage range. (See Geriatric Patients under Dosage and Administration.)
Use with caution in patients with hepatic disease.
Use with caution in patients with renal disease.
Adult Dosage
2.5 to 5 mg (3.8 (3.75)) 6 hourly PO —
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
No data regarding the interactions of Clidinium (Br) was found.
Storage
Caps Store Below 40°C. Protect from Sunlight and Moisture.
Available Brands in Pakistan
No brands are recorded for this generic.